


RESEARCH ARTICLE

# Molecular detection of carbapenemase resistance in *Klebsiella pneumoniae* isolated from urine of patients assessing General Hospital in Keffi, Nasarawa state, Nigeria

Yakubu Boyi Ngwai, Loveth Mary Onehi\*, and Jediel Tsahyel



Department of Microbiology, Nasarawa State University, Keffi, Nigeria

\*Corresponding author

Loveth Mary Onehi

Email: [onehimaryloveth@yahoo.com](mailto:onehimaryloveth@yahoo.com)



## ABSTRACT

**Background:** Carbapenem resistance in *K. pneumoniae* have been reported to emerge in developing and developed countries. Studies on molecular detection of Carbapenem resistance gene in Imipenem resistant *K. pneumoniae* isolated from urine of patients with suspected Urinary tract infection in General Hospital, Keffi, Nigeria. was carried out. Methods: A total of two hundred and ten (210) urine samples were collected from patients and *K. pneumoniae* was isolated and identified using standard microbiological method. The Antibiotic susceptibility test for the isolates was carried out and interpreted in accordance with Clinical and Laboratory Standard Institute (CLSI) protocol. The Molecular detection of Carbapenem resistance gene were carried out using Polymerase Chain Reaction (PCR) method. The occurrence of *K. pneumoniae* was 46(23.3%). Results: The highest occurrence of *K. pneumoniae* in relation to age was observed at age 21-30 (27.1%) and lowest was at age  $\geq 50$  (15.00%). In relation to gender the occurrence was higher in females (32.6%) than male (15.7%). The antibiotic resistance of *K. pneumoniae* showed that the isolates were more resistant to Sulphamethoxazole/Trimethoprim (89.7%) and less resistant to Gentamicin (30.6%) and Imipenem (16.3%). The occurrence of Multidrug resistance (MDR) and pan drug resistance (PDR) isolates were in order of occurrence MDR (83.6%) >PDR (16.3) > XDR (0.0%). The percentage occurrence of Carbapenem resistance gene in *K. pneumoniae* isolates were blaKpc (100%) positive and blaVIM (33.3%) positive. Conclusion: The occurrence of *K. pneumoniae* isolates from urine of suspected urinary tract infections of patients in this study location was high and antibiotics such as Cefexime, Gentamicin and Imipenem were very effective against the *K. pneumoniae* isolates. Also, most of the isolates were multi-drug resistance (MDR). In addition, KPC and VIM genes were predominantly detected in imipenem resistant isolates.

**Keywords:** Carbapenem resistance; molecular identification; *K. pneumoniae*; urinary tract infection

Received: 03 December 2022, revised: 25 December 2022, Published: 03 January 2023

**Citation:** Ngwai, Y.B., Onehi, L.M., and Tsahyel J. (2023). Molecular detection of carbapenemase resistance in *Klebsiella pneumoniae* isolated from urine of patients assessing General Hospital in Keffi, Nasarawa state, Nigeria. *AROC in Pharmaceutical and Biotechnology*. 3(1);01-07, <https://doi.org/10.53858/arocpb03010107>

## 1.0 Introduction

*Klebsiella* (*K.*) *pneumoniae* is a Gram-negative opportunistic nosocomial bacterial pathogen. It is involved in several localized and disseminated hospital-acquired infections such as burns infections, sepsis, respiratory and gastrointestinal tract infections, urinary tract infections, pyogenic liver abscesses, and soft tissue and wound infection [1]. The emergence of carbapenem-resistant *K. pneumoniae* (CRKP) strains has become an ultimate challenge for public health globally due to their ability to disseminate rapidly in the hospital environment and their extended antibiotic resistance phenotypes [2].

In 2001, the first *K. pneumoniae* isolate with KPC-2 production was identified in the USA. There are

many mechanisms in *K. pneumoniae* that can drive carbapenem resistance; KPC-2 production is just one [3]. A few years later, outbreaks began to appear in several countries. Nowadays, it is the most common carbapenemase-producing Enterobacterales (CPE), and is considered one of the most rapidly growing global threats due to the high mortality in hospital-associated infections [4].

In 2017, CRKP was classified among those global critical pathogens listed by WHO concerning discovering and developing new antibiotics [5]. In Nigeria, *K. pneumoniae* was among the most common causes of lower respiratory tract infections, neonatal septicemia, and bacteremia in children [6, 7]. Infections with multidrug-resistant (MDR) pathogens impose a significant and increasing burden on both patients and healthcare providers

[8]. Among MDR pathogens, *Klebsiella pneumoniae* (*K. pneumoniae* or KP) is one of the world's most dangerous superbugs; and becoming resistant to virtually every antibiotic available today [9].

Carbapenem class of antibiotics consists of highly effective agents commonly used for the treatment of severe or high-risk bacterial infections [10]. This class of antibiotics is usually reserved for known or suspected MDR bacterial infections [11]. Similar to penicillins and cephalosporins, carbapenems are members of the  $\beta$ -lactam class of antibiotics, which kill bacteria by binding to penicillin binding proteins, thus inhibiting bacterial cell wall synthesis [12].

Many countries have experienced a dramatic upswing in the prevalence of Enterobacteriaceae that produce both extended spectrum  $\beta$ -lactamases (ESBLs) and carbapenemases such as the *Klebsiella pneumoniae* carbapenemases (KPC) [13, 14]. As of 2013, 70% of *Klebsiella pneumoniae* isolates are resistant to third generation cephalosporins and 60% are resistant to carbapenems [15]. The growing resistance and difficulty of treating such multi-drug resistance Enterobacteriaceae has led to the renaissance of the use of antibiotics such as colistin, which was discovered in the 1950s but rarely used until recently due to the unattractive levels of toxicity [16, 17]

Unfortunately, no information or data about the incidence or otherwise is available in Nigeria despite the fact that it is a significant health problem even in the developed world. Therefore, the aim of the present study is to carry out molecular detection of carbapenemase resistance in *Klebsiella pneumoniae* isolated from urine of patients assessing General Hospital in Keffi, Nasarawa state, Nigeria

## 2.0 Materials and Methods

### 2.1 Media and Reagents

Nutrient Agar (NA), Nutrient Broth (NB), Xylose Lysine Deoxycholate (XLD) agar, MacConkey Agar (MCA), Mueller-Hilton Agar (MHA), Simmons Citrate Agar (SCA) Methyl Red (MR), Voges-Proskauer (VP), Peptone Water (PW). BashingBead™ Buffer (Zymo Research, Made in USA), Genomic Lysis Buffer (Zymo Research, Made in USA), DNA Pre-Wash Buffer (Zymo Research, Made in USA), g-DNA Wash Buffer (Zymo Research, Made in USA), DNA Elution Buffer (Zymo Research, Made in USA), Sterile Nuclease – free water (VWR, Solon, OH), OneTaq® Quick-Load® 2X. Master Mix (New England BioLabs,), Quick-Load® Purple 100 bp DNA Ladder

(New England BioLabs,), Crystal Violet, Kovac's reagent, Potassium hydroxide, beta-naphthol.

### 2.2 Antibiotics

Amoxicillin (AML:10  $\mu$ g), Ampicillin (AMP:10  $\mu$ g), Cefexime (CFM:5  $\mu$ g), Ceftriaxone (CRO:30  $\mu$ g), Ciprofloxacin (CIP:5  $\mu$ g), Gentamicin (CN:30  $\mu$ g), Imipenem (IMP:10  $\mu$ g), Streptomycin (S:30  $\mu$ g) were from Oxoid, Ltd (U.K).

### 2.3 Study Area and Location

The study area is Keffi metropolis is located between longitude 8-5 S° and latitude 7°N and above the sea level of 630m. Keffi is approximately 53km away from the Federal Capital Territory, Abuja and 128km away from the state capital Lafia [18]. This study was carried out in Keffi, Nasarawa State, Nigeria General Hospital, Keffi.

### 2.4 Sample Collection

The ethical approval was obtained from the Ministry of Health Lafia. A total number of 210 urine samples was collected from General Hospital Keffi and then transported using ice box to the Microbiology laboratory in Nasarawa State University, Keffi, for analysis.

### 2.5 Isolation of *Klebsiella pneumoniae*

The *K. pneumoniae* was isolated from the urine samples by modification of the method earlier described Cheesbrough, [19]. A loopful was streaked across MacConkey agar and incubated at 37°C for 24 h. Pink mucoid colonies on MacConkey was selected and cultured on Xylose Lysine Deoxycholate (XLD) agar. Yellow colonies formed on XLD agar which was taken as suspect *K. pneumoniae*.

### 2.6 Identification of *Klebsiella pneumoniae*

The Identification of *Klebsiella pneumoniae* was done using the commercial biochemical kit (KB003 H125™). Gram staining of suspect organisms was carried out as described previously by Cheesbrough, [19]. The presumptive *K. pneumoniae* isolates that were Gram negative, rod shape, indole negative, methyl red negative, citrate positive, and Voges-Proskauer negative were confirmed using KB003 H125 Kit following the manufacturer's instruction

### 2.7 Antibiotics Susceptibility Testing

The antimicrobial susceptibility testing of the *K. pneumoniae* isolates were carried out as earlier described by Clinical and Laboratory Standard Institute [20]. Pure colonies of *K. pneumoniae* isolates were inoculated into 5 ml sterile 0.85%

(w/v) NaCl (normal saline) and the turbidity of the isolates was adjusted to the turbidity equivalent to 0.5 McFarland's standard. The McFarland's standard was prepared as follows: 0.5ml of 1.172% (w/v) BaCl<sub>2</sub>H<sub>2</sub>O was added into 99.5ml of 1% (w/v) H<sub>2</sub>S<sub>04</sub>. A sterile swab stick was soaked in the standardized bacteria suspension and streaked on Mueller-hinton agar figures so as to have influent growth and antibiotics disc were aseptically placed at the centre of the figures and allowed to stand for 1 hour for pre-diffusion was used to evaluate the susceptibility or resistance of *K. pneumoniae* isolates against Ciprofloxacin 5 µg, Streptomycin 10 µg, Trimethoprim 25 µg, Gentamicin 30 µg, Imipenem 10 µg, Ceftriaxone 30 µg, Cefixime 5 µg, Amoxicillin 10µg, Ampicillin 10µg (Oxoid, UK). The figures were incubated at 37°C for 24 h. After incubation, the inhibition zones were measured and interpreted by the recommendations of the Clinical and Laboratory Standards Institute.

## 2.8 Determination of Multiple Antibiotics Resistance (MAR) Index of the isolates

The MAR index of the antibiotics resistant isolates was determined using the formula MAR Index = No. antibiotics isolates was resistant to / No. of antibiotics tested as described previously [21]

## 2.9 Classification of Antibiotics Resistance of the isolates

Antibiotic resistance in the isolates was classified into: multi drug resistance (MDR), extensive drug resistance (XDR), pan drug resistance (PDR) and non-multi drug resistance (NMDR) [22]

## 2.10 DNA Extraction

Purification of *K. pneumoniae* was done on MacConkey agar, and following Zymoresearch, 2018 manufacturer's instruction *K. pneumoniae* was isolated from a 24hours culture. Estimation of concentration, purity and yield of DNA sample was carried out using absorbance method with the spectrophotometer (Nanodrop 1000). DNA purity was estimated by calculating the A<sub>260</sub>/A<sub>280</sub> ratio [23] and this was done with spectrophotometer's computer software (where A<sub>260</sub>/A<sub>280</sub> ratio ranges from 1.7-1.9)

## 2.11 DNA Amplification

The presence of genes (KPC, VIM, SPM, IPM and OXA) were tested using primer sets and conditions listed in Table below. PCR cocktail of 25µl was prepared (4µl of DNA, 2µl of forward primer, 2µl of reverse primer, 12.5µl of Master mix, 4.5µl of Nuclease free sterile H<sub>2</sub>O) in tubes then placed in a thermocycler (Thermofisher Scientific, Finland) Initial denaturation temperature 95°C for 5min, 35 cycles of amplification took place at second denaturation at 94°C for 45min, annealed at 60°C for 40sec, extended at 35°C 1min, final extension at 72°C for 5min and hold 4°C. The primers sequence and amplicon size for carbapenemase resistant genes are presented in table below.

blaSPM (271)= F: AAAATCTGGGTACGCAAACG  
R: ACATTATCCGCTGGAACA  
blaVIM (502)= F: GTGTTTGGTCGCATATCGCAA  
R: ATTCAGCCAGATCGGCATCGG  
blakpc (924)= F: GGTTTGGCGATCTGGTTTTTC  
R: CGGAATGGCTCATCACGATC

## 2.12 Agarose Gel Electrophoresis

Ten microliter of the PCR products and 10 µl DNA ladder (Purple 100 bp DNA Ladder, New England BioLabs) was analyzed by electrophoresis on 1% TAE agarose gel containing 0.5 µl of ethidium bromide pipetted into well created with comb. Electrophoresis was run at 100 volts for 1 hour, after which DNA amplicons were then viewed on a UV trans-illuminator.

## 3.0 Results

### 3.1 Isolation and Identification of *Klebsiella pneumoniae*

The cultural, morphological, and biochemical characteristics *Klebsiella pneumoniae* from isolated from urine of patients is as given in Table 1 Pinkish with mucoid colony on MCA which grew with yellowish on XLD agar, was Gram negative rod and biochemical reactions namely: Indole negative, methyl red negative, Voges-Proskauer positive, Citrate positive, ONPG- negative indicated *K. pneumoniae*

**Table 1:** Cultural, Morphological and Biochemical characteristics of *Klebsiella pneumoniae* isolates.

Cultural characteristics	Morphological characteristics		Biochemical Characteristics							
	Gram reaction	Morphology	IND	MR	VP	CT	ONPG	ORN	UR	H <sub>2</sub> S
Pink and mucor colony on MCA and yellowish on XLD agar	-	Rod	-	-	+	+	-	-	-	-

+ = Positive, - = negative, IND = Indole; MR = Methyl red; VP= Voges-Proskauer, CT = Citrate, ORN = Ornithine; ONPG = Ortho-Nitrophenyl-β-galactosidase, UR = Urease, H<sub>2</sub>S = Hydrogen Sulphide, Mal = Malonate

### 3.2 Occurrence of *Klebsiella pneumoniae*

The occurrence of *Klebsiella pneumoniae* isolates were recorded 49(23.3%) out of the 210 urine samples. The occurrences of *K. pneumoniae* in relation to age and gender of the patients are shown in Table 2. The highest occurrence of *K. pneumoniae* in the patients were observed at age 21-30 (27.1%) followed by 31-40 (25.0%), 41-50 (20.6%) and the least at age  $\geq 50$  (15.00%) as shown in Table 2. In relation to gender of the patients, the occurrence of *K. pneumoniae* isolates was higher in females (32.6%) and the male at (15.7%) as shown in Table 3. The occurrence of *K. pneumoniae* isolates in relation to age and gender of UTI patients were not significant ( $P > 0.05$ )

**Table 2:** Occurrence of *Klebsiella pneumoniae* relative to age from urine of patients with suspected Urinary Tract Infection in General Hospital Keffi, Nigeria.

Age	No. of Samples	No (%) of <i>Klebsiella pneumoniae</i>
11-20	32	6 (18.7)
21-30	81	22 (27.1)
31-40	48	12 (25.0)
41-50	29	6 (20.66)
$\geq 50$	20	3 (15.0)
<b>Total</b>	<b>210</b>	<b>49 (23.3)</b>

**Table 3:** Occurrence of *Klebsiella pneumoniae* relative to gender from urine of patients with suspected Urinary Tract Infection in General Hospital, Keffi, Nigeria.

Gender	No. of Samples	No. (%) of <i>Klebsiella pneumoniae</i>
Male	95	15(15.7)
Female	104	34(32.6)
<b>Total</b>	<b>210</b>	<b>49 (12.8)</b>

### 3.3 Antibiotic Resistance

The antibiotic resistance of *K. pneumoniae* is as shown in Table 4. The *K. pneumoniae* were more resistant to Sulphamethoxazole/Trimethoprim (89.7%) followed by ampicillin and streptomycin (85.7%) and Ciprofloxacin (65.3%) but less resistant to Cefexime (46.9%), Gentamicin (30.6%) and Imipenem (16.3%).

**Table 4:** Antibiotic Resistant of *Klebsiella pneumoniae* isolated from urine with suspected Urinary Tract Infection in General Hospital, Keffi, Nigeria.

Antibiotics	Content ( $\mu\text{g}$ )	Resistance (n = 49)
Amoxicillin/clavulanic acid (AMC)	10	31(63.2)
Ampicillin (AMP)	10	42(85.7)
Cefexime (CFM)	5	23(46.9)
Cefotaxime (CTX)	30	26(53.0)
Ciprofloxacin (CIP)	5	32(65.3)
Gentamicin (CN)	30	15(30.6)
Imipenem (IMP)	10	8(16.3)
Ceftazidime (CAZ)	30	27(55.1)
Streptomycin (S)	30	42(85.7)
Sulphamethoxazole/Trimethoprim (SXT)	25	44 (89.7)

### 3.4 Antibiotic Resistance of Phenotypes

The most common antibiotic resistant phenotypes were CTX, CIP, CFM, AMC, AMP, SXT, CN, S (14.2%) and CTX, CIP, CFM, AMC, AMP, SXT, S (12.2%) as shown in Table 5.

**Table 5:** Antibiotic Resistant phenotype of *Klebsiella pneumoniae* isolated from urine with suspected Urinary Tract infection in General Hospital, Keffi, Nigeria.

Antibiotic Resistant Phenotypes	Frequency (%) (n = 49)
AMC, AMP, SXT, S	2(4.0)
CTX, AMC, SXT, S	1(2.0)
CIP, AMC, AMP, SXT	1(2.0)
CAZ, AMC, AMP, SXT, S	2(4.0)
IMP, CFM, AMC, AMP, S	1(2.0)
CIP, AMC, AMP, SXT, S	1(2.0)
CFM, AMC, AMP, SXT, S	5(10.2)
AMC, AMP, SXT, CN, S	1(2.0)
CTX, AMC, AMP, SXT, S	1(2.0)
CIP, AMC, AMP, SXT, CN, S	2(4.0)
IMP, CTX, CFM, CAZ, SXT, S	1(2.0)
CTX, CFM, AMC, AMP, SXT, S	1(2.0)
CTX, CIP, AMC, AMP, SXT, S	1(2.0)
CIP, CFM, AMC, AMP, SXT, S	2(4.0)
CTX, CIP, AMC, AMP, SXT, S	1(2.0)
CIP, CAZ, AMC, AMP, SXT, S	1(2.0)
CTX, CIP, CFM, CAZ, AMC, SXT, S	1(2.0)
IMP, CIP, CAZ, AMC, AMP, SXT, S	1(2.0)
CIP, CFM, CAZ, AMC, AMP, SXT, S	1(2.0)
CTX, CIP, CFM, AMC, AMP, SXT, S	6(12.2)
CTX, CFM, CAZ, AMC, AMP, SXT, S	1(2.0)
CTX, CIP, CFM, CAZ, AMC, AMP, SXT	1(2.0)
IMP, CTX, CAZ, AMC, AMP, SXT, S	1(2.0)
CTX, CIP, CFM, CAZ, AMC, AMP, SXT, S	2(4.0)
IMP, CIP, CAZ, AMC, AMP, SXT, CN, S	1(2.0)
CTX, CIP, CFM, AMC, AMP, SXT, CN, S	7(14.2)
CRO, CIP, CFM, F, AML, AMP, SXT, CN, S	2(4.0)
IMP, CTX, CIP, CFM, CAZ, AMC, AMP, SXT, CN, S	1(2.0)

AMC = Amoxicillin/clavulanic acid, AMP = Ampicillin, CFM = Cefexime, CTX = Cefotaxime, CIP = Ciprofloxacin, CN = Gentamicin, IMP = Imipenem, CAZ= Ceftazidime, S = Streptomycin, SXT = Sulphamethoxazole/Trimethoprim

### 3.5 Multiple Antibiotic Resistance (MAR) Index

Multiple antibiotic resistance is defined as resistance to more than two antibiotics tested. The MAR indices of the isolates is as shown in Table 6 were  $> 0.2$  with the most common being 0.7(24.4%) and 0.8 (22.4%).

### 3.6 Categories of Antibiotics

The distribution of the isolates into different categories of antibiotic resistance namely multi-drug resistance (MDR), Extended drug resistance (XDR), Pan drug resistance (PDR) is as shown in Table 7. The order of percentage occurrence was MDR (83.6%)  $>$  PDR (16.3)  $>$  XDR (0.0%)



**Table 6:** Multiple Antibiotic Resistance (MAR) Index of *Klebsiella pneumoniae* isolated from urine of patients with suspected Urinary Tract Infection in General Hospital, Keffi

No of Antibiotics Resistant to (a)	No of Antibiotics tested (b)	MAR index (a/b)	Frequency (%) MAR Isolates (n = 49)
10	10	1.0	1 (2.0)
9	10	0.9	2 (4.0)
8	10	0.8	11 (22.4)
7	10	0.7	12 (24.4)
6	10	0.6	10 (20.4)
5	10	0.5	9 (18.3)
4	10	0.4	4 (8.1)
3	10	0.3	0 (0)
2	10	0.2	0 (0)
1	10	0.1	0 (0)


**Table 7:** Classification of categories of Antibiotics Resistance in *Klebsiella pneumoniae* from urine of patients with suspected urinary tract infection in General Hospital, Keffi, Nigeria

Categories of Antibiotic Resistance	Frequency (%) (n=49)
MDR	41 (83.6)
XDR	0 (0.0)
PDR	8 (16.3)


MDR = Multi-drug resistance (non-susceptible to  $\geq 1$  agent in  $\geq 3$  antimicrobial); XDR = Extensive drug resistance (non-susceptible to  $\geq 1$  agent in all but  $\leq 2$  antimicrobial categories); PDR = Pan drug resistance (non-susceptible to all antimicrobials listed)

### 3.7 Molecular Detection of Carbapenem Resistance Gene in *K. pneumoniae* Isolates

The genotypic detection of carbapenem-resistant genes to Imipenem resistant *K. pneumoniae* isolates are as shown in Table 4 and figures 1 and 2. The 3 resistant Imipenem resistant *K. pneumoniae* isolates were *blaKPC* (100%) positive and *blaVIM* (33.3%) positive.



**Figure 1:** Agarose gel electrophoresis showing the amplified *blaKPC* gene. Lane uk3, uk11 and uk29 represent the *blaKPC* gene bands at 1000 bp while lane L represents the 100bp molecular ladder.



**Figure 2:** Agarose gel electrophoresis showing the amplified *blaVIM* gene. Lane uk11 represents the *blaVIM* gene band at 500 bp while lane L represents the 100bp molecular ladder

### 4.0 Discussion

Carbapenem resistance in *K. pneumoniae* have been reported to emerge in developing and developed countries [24]. Studies on molecular detection of Carbapenem resistance gene in Imipenem resistant *K. pneumoniae* isolates in the study location was carried out. The occurrence of *K. pneumoniae* from urine of patients with suspected Urinary Tract Infection in this study was not new as this finding is similar to studies earlier reported [23][25]. The percentage of occurrence of *K. pneumoniae* as observed in this study was less than 26.9% and 75.7% as earlier reported by [23][26]. The occurrence of *K. pneumoniae* in urine of suspected urinary tract infection was an indication that such organism may be responsible for urinary tract infection and this finding is in agreement with the study earlier reported [24, 26] that *K. pneumoniae* is the most common etiological agent of urinary tract infections.

The occurrence of *K. pneumoniae* from urine of patients with suspected urinary tract infections in relation to age as observed in this study was high in age 21-30 years and this finding is in agreement with the study earlier reported [27] who reported high prevalence of *K. pneumoniae* from urine of patients in same age. The high occurrence of *K. pneumoniae* in age group in this study was an indication the level of hygiene of that age group was low or the level of sexual activity maybe high [28].

The findings in this study also shows the occurrence of *K. pneumoniae* was high in female than male and this is in agreement with the study earlier described

Gonzalez-Padilla et al., [28]. The high prevalence of *K. pneumoniae* in females compared to may be due to difference in the anatomy of the reproductive system where women had very short urethra, closeness to the anus [23]. The percentage of *K. pneumoniae* in female in this study was less than 75% reported in (Wadekar & Sathish 2017), less than 69% in females which is higher than 31.0% in males [23] less than 59.3% in females which higher than 40.7% in males [29].

The high resistance of *K. pneumoniae* isolates to Suphamethoxazole/Trimethopin, Streptomycin, Ampicillin and Ciprofloxacin as observed in this study was not new. This may be due to indiscriminate use of these antibiotics in the study location. The percentage resistance of the isolates to Suphamethoxazole/Trimethopin as observed in this study was higher than 85.8%, and 67.9% earlier reported [29]

The low resistance of the isolates Ceftriaxone, Gentamicin and Imipenem observed in this study was an indication that these antibiotics may not have been abused in the study location. The percentage resistance of the isolates, *K. pneumoniae* to Gentamicin, Imipenem, was less than 47.8% and 11.2% reported by Akhtar et al., 2016. The low resistance of the *K. pneumoniae* isolates to antibiotics mentioned justify their use as a common drug of choice for treatment caused by gram negative bacterial infections [23].

The occurrence of Multi-drug resistance (MDR) *K. pneumoniae* from urine of patients observed in this study was expected and it is in agreement with the study earlier reported [25] that Multi-drug resistance (MDR) *K. pneumoniae* have been associated with urinary tract infection, thus difficult to be treated. The percentage occurrence of Multi-drug resistance (MDR) *K. pneumoniae* as observed in this study was less than 50.7% reported by Alhashash et al., [25]

The detection of Carbapenem resistance gene KPC and VIM in Imipenem resistant isolates as observed in this study is in agreement with the study earlier reported [30]. The detection of this gene in the resistant *K. pneumoniae* isolates was an indication the gene may be responsible for resistance to Imipenem. Although other genes such as SPM, NDM and IPM were not detected in Imipenem resistant *K. pneumoniae* isolates in this study but have been reported by Ojdana et al. [26] to be responsible for resistance to carbapenem antibiotics. The percentage detection of KPC gene in resistant *K. pneumoniae* isolates observed in this study was higher than 48.8% reported by previous researcher

## 5.0 Conclusion

The occurrence of *K. pneumoniae* isolates from urine of suspected urinary tract infections of patients in this study location was high and antibiotics such as Cefexime, Gentamicin and Imipenem were very effective against the *K. pneumoniae* isolates. Also, most of the isolates were multi-drug resistance (MDR). In addition, KPC and VIM genes were predominantly detected in imipenem resistant isolates.

**Funding:** This research did not receive any specific grant from funding agencies in the public, commercial, or not-for profit sectors.

**Author's contributions:** All authors contributed to the manuscript and approved the published version

**Conflict of interest:** The authors declared no conflict of interest.

**Acknowledgements:** Not Applicable

## References

1. Li, B., et al., Molecular pathogenesis of Klebsiella pneumoniae. Future microbiology, 2014. 9(9): p. 1071-1081.
2. Yao, H., et al., Emergence of carbapenem-resistant hypervirulent Klebsiella pneumoniae. The Lancet Infectious Diseases, 2018. 18(1): p. 25.
3. Roh, K.H., et al., Isolation of a Klebsiella pneumoniae isolate of sequence type 258 producing KPC-2 carbapenemase in Korea. The Korean Journal of Laboratory Medicine, 2011. 31(4): p. 298.
4. Touati, A. and A. Mairi, Epidemiology of carbapenemase-producing Enterobacterales in the Middle East: a systematic review. Expert Review of Anti-infective Therapy, 2020. 18(3): p. 241-250.
5. Yan, J., et al., Multidrug resistance mechanisms of carbapenem resistant Klebsiella pneumoniae strains isolated in Chongqing, China. Annals of laboratory medicine, 2017. 37(5): p. 398-407.
6. Uzoamaka, M., et al., Bacterial etiology of lower respiratory tract infections and their antimicrobial susceptibility. The American Journal of the Medical Sciences, 2017. 354(5): p. 471-475.
7. Egbe, C.A., C. Ndiokwere, and R. Omoregie, Microbiology of lower respiratory tract infections in Benin City, Nigeria. The Malaysian journal of medical sciences: MJMS, 2011. 18(2): p. 27.
8. Marchaim, D., et al., The burden of multidrug-resistant organisms on tertiary hospitals posed by patients with recent stays in long-term acute care facilities. American journal of infection control, 2012. 40(8): p. 760-765.
9. Woldu, M., Klebsiella pneumoniae and its growing concern in healthcare settings. Clin Exp Pharmacol, 2016. 6(1): p. 1-7.

10. Nicolau, D.P., Carbapenems: a potent class of antibiotics. *Expert opinion on pharmacotherapy*, 2008. 9(1): p. 23-37.
11. Perez, F. and D. Van Duin, Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients. *Cleveland Clinic journal of medicine*, 2013. 80(4): p. 225.
12. Coulthurst, S.J., A.M. Barnard, and G.P. Salmond, Regulation and biosynthesis of carbapenem antibiotics in bacteria. *Nature Reviews Microbiology*, 2005. 3(4): p. 295-306.
13. Remya, P., M. Shanthi, and U. Sekar, Prevalence of blaKPC and its occurrence with other beta-lactamases in *Klebsiella pneumoniae*. *Journal of Laboratory Physicians*, 2018. 10(04): p. 387-391.
14. Sah, S.K. and S. Hemalatha, Extended spectrum Beta lactamase (ESBL) Mechanism of antibiotic resistance and Epidemiology. *Int J pharmtech Res*, 2015. 7(2): p. 303-9.
15. Breurec, S., et al., *Klebsiella pneumoniae* resistant to third-generation cephalosporins in five African and two Vietnamese major towns: multiclonal population structure with two major international clonal groups, CG15 and CG258. *Clinical Microbiology and Infection*, 2013. 19(4): p. 349-355.
16. Schultsz, C. and S. Geerlings, Plasmid-mediated resistance in Enterobacteriaceae. *Drugs*, 2012. 72(1): p. 1-16.
17. Giamarellou, H. and G. Poulakou, Multidrug-resistant gram-negative infections. *Drugs*, 2009. 69(14): p. 1879-1901.
18. Akwa, V., et al., Geographical Perspective of Nasarawa State. Onaivi Printing and Publishing Company Ltd. Keffi, Nasarawa State, Nigeria, 2007: p. 34-35.
19. Cheesbrough, M., *District laboratory practice in tropical countries, part 2*. 2005: Cambridge university press.
20. Huse, H., et al., Evaluation of oxacillin and cefoxitin disk diffusion and MIC breakpoints established by the clinical and laboratory standards institute for detection of mecA-mediated oxacillin resistance in *Staphylococcus schleiferi*. *Journal of clinical microbiology*, 2018. 56(2): p. e01653-17.
21. Osundiya, O., R. Oladele, and O. Oduyebo, Multiple antibiotic resistance (MAR) indices of *Pseudomonas* and *Klebsiella* species isolates in Lagos University Teaching Hospital. *African Journal of Clinical and Experimental Microbiology*, 2013. 14(3): p. 164-168.
22. Harwood, V.J., J. Whitlock, and V. Withington, Classification of antibiotic resistance patterns of indicator bacteria by discriminant analysis: use in predicting the source of fecal contamination in subtropical waters. *Applied and Environmental Microbiology*, 2000. 66(9): p. 3698-3704.
23. Lawal, B., et al., Human Genetic Markers and Structural Prediction of *Plasmodium falciparum* Multidrug Resistance Gene (pfmdr1) for Ligand Binding in Pregnant Women Attending General Hospital Minna. *Journal of Environmental and Public Health*, 2018. 2018: p. 3984316.
24. Shahina, Z., et al., A study of antibacterial susceptibility and resistance pattern of *E. coli* causing urinary tract infection in Chittagong, Bangladesh. *Asian J. Biol. Sci*, 2011. 4: p. 548-555.
25. Alhashash, F., et al., Multidrug-resistant *Escherichia coli* bacteremia. *Emerging infectious diseases*, 2013. 19(10): p. 1699.
26. Ojdana, D., et al., Genetic basis of enzymatic resistance of *E. coli* to aminoglycosides. *Advances in medical sciences*, 2018. 63(1): p. 9-13.
27. Tanko, N., Retrospective studies on the prevalence of uropathogens in sokoto metropolis. *African Journal of Microbiology Research*, 2015. 9(20): p. 1366-1370.
28. Gonzalez-Padilla, M., et al., Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant *Klebsiella pneumoniae*. *Journal of Antimicrobial Chemotherapy*, 2015. 70(3): p. 905-913.
29. Akhtar, N., R. Rahman, and S. Sultana, Antimicrobial sensitivity pattern of *Escherichia coli* causing urinary tract infection in Bangladeshi patients. *American Journal of Microbiological Research*, 2016. 4(4): p. 122-125.
30. Pezzani, M.D. and S. Antinori, Introduction to urinary tract infections: An overview on epidemiology, risk factors, microbiology and treatment options. *Imaging and Intervention in Urinary Tract Infections and Urosepsis*, 2018: p. 7-16.

**Submit your article to AROC JOURNALS**  
 -AROC in Pharmaceutical and Biotechnology  
 -AROC in Agriculture  
 -AROC in Bioinformatics  
 -AROC in Food and Nutrition  
 -AROC in Natural Product Research  
 -BIOMED Natural and Applied Science  
 Visit: <https://arocjournal.com/>

Copyright © 2023 Ngwai et al. This is an open access article distributed under the terms and conditions of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>)